Smith & Nephew pays $782 million to acquire Healthpoint Biotherapeutics, hoping to enhance its position in bioactives.

Smith & Nephew (FTSE:SN, NYSE:SNN) completed the acquisition of substantially all the assets of Healthpoint Biotherapeutics, paying $782 million in cash financed by the company's existing cash resources and bank facilities. 

The purchase of Healthpoint gives Smith & Nephew a strong position in bioactives, the fastest growing area of advanced wound management, according to the press release.